A decade into reformulating Pfizer’s oral renal cell carcinoma drug Inlyta (axitinib) into a treatment that can be injected ...

With Pfizer’s revenue and share price slumping after the drugmaker skyrocketed to new heights during the pandemic, the ...

Treatments for multiple sclerosis have long focused on slowing or stopping the acute disease process, which moves quickly and ...

A trial of Biogen’s spinal muscular atrophy (SMA) therapy Spinraza (nusinersen) suggests that a higher dose provides benefits ...

Is your company bracing for Milton or working to provide aid in anticipation of the storm? | Pfizer—which opened a global hub ...

While recent CDC guidance threatens to shrink the market for a new class of immunizations, GSK continues to build the case ...

Merck & Co. hopes a new positive trial readout can return Keytruda to glory in head and neck cancer. | Merck & Co. hopes a ...

The Congressional Budget Office found that only one out of the seven policies it reviewed would create notable reductions in ...

A new survey commissioned by Big Pharma Roche has found that half of those polled “have either limited or no awareness” of ...

With an estimated 2 million people in the United States taking copycat vers | A compounding industry group has sued the FDA, ...

Eversana is increasing its reach across the global pharmaceutical industry. | Eversana is increasing its reach across the ...

Off the scrapheap of discarded drugs and on its way to becoming the most highly anticipated approval of 2024, Bristol Myers ...